HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

L’Oreal Introduces Dermocosmetic Brands, Kerastase To “Sixth Continent”

This article was originally published in The Rose Sheet

Executive Summary

Travelers in Asia and the Americas will have the opportunity to purchase Vichy, La-Roche Posay and Kerastase products through L’Oreal DermaCenters and Kerastase Hair Studios within the coming months, the firm announces. In 2013, L’Oreal captured 21.3% of beauty sales in the $60 billion global travel-retail market.

You may also be interested in...



In Brief

L’Oreal considers travel retail a “sixth continent” in terms of consumer reach and creates a new division to better serve the segment; firm separately announces it will shutter its mail-order division. More news in brief.

Fragrance Creators Association Readies New Consumer Website To Cap ‘Year For The Public’

Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.

FDA’s Cannabidiol Crackdown: What Do Warning Letters Say About CBD In Cosmetics?

Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.

UsernamePublicRestriction

Register

RS019275

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel